市場調査レポート
商品コード
1337642
先端巨大症市場 - 市場の洞察、疫学、市場予測:2032年Acromegaly - Market Insight, Epidemiology And Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
先端巨大症市場 - 市場の洞察、疫学、市場予測:2032年 |
出版日: 2023年08月01日
発行: DelveInsight
ページ情報: 英文 147 Pages
納期: 1~3営業日
|
先端巨大症は、成人が罹患するまれな緩徐進行性の後天性疾患です。下垂体から成長ホルモン(GH)が過剰に分泌されます。下垂体は頭蓋骨の底部近くにある小さな腺で、いくつかのホルモンを貯蔵し、身体の必要に応じて血流に放出します。これらのホルモンは、さまざまな身体機能を調節します。ほとんどの患者さんにおいて、先端巨大症は下垂体から発生する良性腫瘍(腺腫)の増殖によって引き起こされます。先端巨大症の症状には、手、腕、足、頭の骨の異常な肥大があります。顎および頭蓋骨の前面の骨の増大は、典型的に最も明らかな骨の変化です。
先端巨大症の一般的な徴候や症状は、手足の肥大です。例えば、以前は合っていた指輪がはめられなくなったり、靴のサイズが徐々に大きくなったりします。また、下あごや眉骨が突出し、鼻が大きくなり、唇が厚くなり、歯の間隔が広がるなど、顔の形が徐々に変化することもあります。先端巨大症はゆっくりと進行するため、初期の徴候が何年もはっきりしないこともあります。古い写真と新しい写真を見比べて初めて身体的変化に気づくこともあります。全体的に、先端巨大症の徴候や症状は人によって異なる傾向があり、手足の肥大、顔面骨、唇、鼻、舌などの顔面の肥大、ザラザラした脂性で厚くなった皮膚、過度の発汗、体臭などがあります。
先端巨大症は、体内の成長ホルモン(GH)の過剰レベルによって引き起こされるまれな疾患です。ほとんどの患者さんでは、GHの過剰値は下垂体の良性(非がん性)腫瘍(下垂体腺腫)によって引き起こされます。ほとんどの腺腫は、ソマトトロープ細胞(GHを正常に分泌する下垂体細胞)と呼ばれる下垂体細胞の過剰な増殖から形成されます。ほとんどの患者において、この疾患は散発性であり、遺伝性の遺伝子変異によるものではありません。
下垂体腺腫で現在使用されている最良のバイオマーカーはKi-67核標識指数です。Ki-67は細胞周期を通じて発現し、MIB-1モノクローナル抗体を用いて日常的に検出されます。このアッセイは有用であるが、完全な信頼性はないです。細胞周期の制御に関与する細胞性腫瘍抗原であるp53もまた、下垂体腺腫を同定する可能性のあるバイオマーカーとして使用されています。
2022年、米国で診断された先端巨大症の有病者総数は27,000例であり、2032年までに増加すると予測されます。欧州4ヶ国と英国は、2022年に21,000例の先端巨大症の診断有病者数を占め、2032年までに増加すると予測されます。日本では、2022年の先端巨大症の腫瘍起源別症例数は、下垂体腫瘍で9,100例、非下垂体腫瘍で480例であり、2032年までに増加すると予測されます。欧州4ヶ国と英国では、2022年の先端巨大症の腫瘍サイズ別症例数は、巨大腺腫が18,300例、微小腺腫が3,050例であり、2032年までに増加するとみられています。
2022年の先端巨大症の市場規模は、米国が主要7ヶ国諸国中最大で7億米ドルでした。欧州4ヶ国カ国のうち、2022年の先端巨大症の市場規模が最も大きいのはドイツで、9,000万米ドルです。欧州4ヶ国カ国の中で最も市場規模が小さいのはスペインで、2022年の市場規模は5,000万米ドルでした。英国における先端巨大症の市場規模は、2022年に1億1,000万米ドルであることがわかっています。
当レポートでは、主要7ヶ国における先端巨大症市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。
DelveInsight's 'Acromegaly - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of Acromegaly historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
The Acromegaly market report provides current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted 7MM Acromegaly market size. The report also covers the Acromegaly procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032
Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. The pituitary gland produces too much growth hormone (GH). The pituitary gland is a small gland located near the base of the skull that stores several hormones and releases them into the bloodstream as needed by the body. These hormones regulate many different bodily functions. In most patients, acromegaly is caused by the growth of a benign tumor (adenoma) arising from the pituitary gland. Symptoms of acromegaly include abnormal enlargement in the hands, arms, feet, legs, and head bones. Enlargement of the bones in the jaws and the front of the skull are typically the most apparent bony changes.
Common signs and symptoms of acromegaly are enlarged hands and feet. For example, patients cannot put on rings that used to fit, and the shoe size has progressively increased. It may also cause gradual changes in the face shape, such as a protruding lower jaw and brow bone, an enlarged nose, thickened lips, and wider spacing between the teeth. Because acromegaly progresses slowly, early signs may not be obvious for years. Sometimes, people notice the physical changes only by comparing old photos with newer ones. Overall, acromegaly signs and symptoms tend to vary from one person to another and may include any of the following: enlarged hands and feet, enlarged facial features, including the facial bones, lips, nose, and tongue, coarse, oily, thickened skin, excessive sweating, and body odor.
Acromegaly is a rare disorder caused by excess levels of growth hormone (GH) in the body. In most patients, excess levels of GH are caused by a benign (noncancerous) tumor in the pituitary gland (pituitary adenoma). Most adenomas form from the excessive growth of a pituitary cell called a somatotrope cell (the pituitary cell that normally secretes GH). In most patients, the disease is sporadic and not due to an inherited genetic mutation.
The best biomarker currently used in Pituitary Adenomas is the Ki-67 nuclear labeling index. It is expressed throughout the cell cycle and routinely detected using the MIB-1 monoclonal antibody. This assay is useful but not perfectly reliable. p53, a cellular tumor antigen involved in cell cycle regulation, has also been used as a possible biomarker for identifying pituitary adenomas.
The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Acromegaly, Tumor Origin-specific Cases of Acromegaly, Gender-specific Cases of Acromegaly, Tumor Size-specific Cases of Acromegaly covering the United States, EU4 (Germany, France, Italy, Spain), UK and Japan from 2019 to 2032.
MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It reduces the production of GH by binding to receptors on specialized cells in the pituitary gland. Being administrated orally, these capsules can serve as an alternative to the current standard-of-care injection therapy available for people living with acromegaly today.
SIGNIFOR LAR (pasireotide): Recordati/Novartis Pharmaceuticals
Novartis Pharmaceuticals developed SIGNIFOR LAR (pasireotide) as an injectable suspension. It is a long-acting release form of pasireotide pamoate, as a powder to be suspended in the provided diluent immediately before intramuscular injection. SIGNIFOR LAR is a somatostatin analog that consists of pasireotide pamoate uniformly distributed within microspheres which are made of biodegradable copolymers of poly (D, L-lactide-co-glycolide) acids (PLGA), and it is available in a vial containing the sterile pasireotide pamoate.
Paltusotine (CRN 00808), developed by Crinetics Pharmaceuticals, is an oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist with potential growth hormone (GH) secretion-inhibiting and antineoplastic activities. It is designed to reduce excess GH secretion from benign pituitary tumors and normalize IGF-1 levels in patients with acromegaly.
CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus' proprietary Fluid Crystal injection depot technology. It is provided as a prefilled syringe, thus not requiring reconstitution or conditioning before administration. Due to the superior ease of handling and administration, CAM2029 can conveniently be administered by patients. It was developed for the treatment of acromegaly and neuroendocrine tumors. This drug offers the potential for enhanced treatment efficacy in patients for whom current treatments provide suboptimal treatment effects.
Acromegaly can start at any time after puberty. However, it occurs more often in middle age, and people are not always aware of their condition. Changes to the body may take place slowly over many years. Although acromegaly is treatable in most people, as symptoms gradually develop, health problems can develop before the disorder is diagnosed and treated.
The current treatment options include surgery, medicines, and radiation therapy. The treatment goals are to control tumor size, return GH and IGF-I levels to normal, improve symptoms, and manage related health problems. Currently, three types (Somatostatin analogs, dopamine agonists, and growth hormone-receptor antagonists) of medicines are used to treat acromegaly. However, they do not provide a cure for the disease. The medicines may be used alone or in combination with each other. The third treatment option is radiation therapy (stereotactic and conventional), which uses high-energy x-rays or particle waves to kill tumor cells. This type of treatment may be recommended if surgery is impossible or fails to remove all tumor tissue, and medicines are not an option.
However, in the current scenario, the treatment method for acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the diseases causing areas and on reducing GH and IGF-1 levels to normal. Although the primary treatment method for acromegaly is transsphenoidal surgery, not all patients are eligible for surgery. Patients diagnosed with microadenomas and those with macroadenomas not close to other key structures in the brain, such as the nerves supplying the eyes or nearby blood vessels, are recommended for surgery.
This section provides the total Acromegaly market size and market size by therapies in the United States.
The total Acromegaly market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Acromegaly market size and market size by therapies in Japan are provided.
This section focuses on the uptake rate of potential drugs recently launched in the Acromegaly market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into therapeutic candidates in Phase II and III stages. It also analyzes key players involved in developing targeted therapeutics.
The report covers collaborations, acquisitions, mergers, licensing, and patent details for Acromegaly emerging therapies.
Approaching reimbursement proactively can positively impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitive market Intelligence analysis of the Acromegaly market using various competitive intelligence tools, including SWOT analysis, market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.